Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:CTORNASDAQ:SKYENASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.07+5.9%$1.08$0.86▼$3.92$64.81M0.09291,267 shs165,356 shsCTORCitius Oncology$0.92+3.4%$0.74$0.55▼$4.42$65.47M-0.171.12 million shs43,465 shsSKYESkye Bioscience$1.87-7.0%$1.81$1.14▼$12.77$57.92M1.74360,744 shs222,400 shsSNYRSynergy CHC Corp. (Uplisting)$2.38+11.2%$2.38$0.12▼$10.00$20.83MN/A738,821 shs102,286 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+3.06%+0.50%-3.81%-30.34%-73.42%CTORCitius Oncology-0.58%+4.75%+29.59%-29.19%+88,509,900.00%SKYESkye Bioscience+3.55%+12.29%+17.54%-36.49%-84.15%SNYRSynergy CHC Corp. (Uplisting)+10.31%+11.46%-2.73%-42.16%+213,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.7292 of 5 stars3.73.00.00.02.61.70.6CTORCitius OncologyN/AN/AN/AN/AN/AN/AN/AN/ASKYESkye Bioscience1.3214 of 5 stars3.51.00.00.02.70.00.0SNYRSynergy CHC Corp. (Uplisting)3.5138 of 5 stars3.80.00.00.03.61.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.33Buy$7.33585.36% UpsideCTORCitius Oncology 3.00Buy$3.00227.87% UpsideSKYESkye Bioscience 3.00Buy$16.60787.70% UpsideSNYRSynergy CHC Corp. (Uplisting) 3.50Strong Buy$10.00320.17% UpsideCurrent Analyst Ratings BreakdownLatest SNYR, CTOR, ABOS, and SKYE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025ABOSAcumen PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/28/2025ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $11.003/21/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.003/21/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/ACTORCitius OncologyN/AN/AN/AN/A($0.22) per shareN/ASKYESkye BioscienceN/AN/AN/AN/A($0.17) per shareN/ASNYRSynergy CHC Corp. (Uplisting)$34.83M0.60N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.94N/AN/AN/AN/A-32.99%-27.99%N/ACTORCitius Oncology-$21.15MN/A0.00∞N/AN/A-43.67%-9.74%N/ASKYESkye Bioscience-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/ASNYRSynergy CHC Corp. (Uplisting)N/AN/A0.004.03N/AN/AN/AN/AN/ALatest SNYR, CTOR, ABOS, and SKYE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SNYRSynergy CHC Corp. (Uplisting)$0.07$0.10+$0.03$0.10$9.03 million$8.17 million5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A3/31/2025Q4 2024SNYRSynergy CHC Corp. (Uplisting)$0.10$0.01-$0.09$0.01$10.55 million$10.30 million3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/A3/20/2025Q4 2024SKYESkye Bioscience-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ASNYRSynergy CHC Corp. (Uplisting)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1410.4310.43CTORCitius Oncology0.080.340.08SKYESkye BioscienceN/A14.1914.19SNYRSynergy CHC Corp. (Uplisting)N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%CTORCitius Oncology70.52%SKYESkye Bioscience21.09%SNYRSynergy CHC Corp. (Uplisting)N/AInsider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%CTORCitius Oncology4.57%SKYESkye Bioscience4.50%SNYRSynergy CHC Corp. (Uplisting)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million55.81 millionOptionableCTORCitius OncologyN/A71.55 million55.17 millionN/ASKYESkye Bioscience1130.98 million29.43 millionOptionableSNYRSynergy CHC Corp. (Uplisting)408.75 millionN/AN/ASNYR, CTOR, ABOS, and SKYE HeadlinesRecent News About These CompaniesSynergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call InformationMay 1, 2025 | globenewswire.comSynergy CHC Stock Short Interest Report | NASDAQ:SNYR | BenzingaApril 17, 2025 | benzinga.comSynergy CHC Reports its Eighth Consecutive Quarter of Profitability and its Fourth Quarter and Full Year 2024 Financial ResultsMarch 31, 2025 | markets.businessinsider.comSynergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call InformationMarch 21, 2025 | markets.businessinsider.comRoth MKM Initiates Coverage of Synergy CHC (SNYR) with Buy RecommendationJanuary 22, 2025 | msn.comSynergy CHC Announces 7th Quarter of ProfitabilityDecember 7, 2024 | markets.businessinsider.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Purchases $2,700,000.00 in StockOctober 25, 2024 | insidertrades.comSynergy CHC Corp. Announces Closing of Initial Public OfferingOctober 24, 2024 | globenewswire.comSynergy CHC Corp. Prices $10.35 Million Initial Public OfferingOctober 22, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThese 3 Cybersecurity Stocks Are Defying the DownturnBy Ryan Hasson | April 29, 2025View These 3 Cybersecurity Stocks Are Defying the DownturnGoogle Is Betting Big on Nuclear Reactors—Should You?By Dan Schmidt | May 9, 2025View Google Is Betting Big on Nuclear Reactors—Should You?BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is LikelyBy Thomas Hughes | May 1, 2025View BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is LikelyAT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?By Leo Miller | May 1, 2025View AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?Is Energy Transfer Undervalued or a Value Trap?By Chris Markoch | May 8, 2025View Is Energy Transfer Undervalued or a Value Trap?SNYR, CTOR, ABOS, and SKYE Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.07 +0.06 (+5.94%) Closing price 04:00 PM EasternExtended Trading$1.02 -0.05 (-4.21%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Citius Oncology NASDAQ:CTOR$0.92 +0.03 (+3.38%) Closing price 03:56 PM EasternExtended Trading$0.92 0.00 (0.00%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Skye Bioscience NASDAQ:SKYE$1.87 -0.14 (-6.97%) Closing price 04:00 PM EasternExtended Trading$1.90 +0.03 (+1.39%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Synergy CHC Corp. (Uplisting) NASDAQ:SNYR$2.38 +0.24 (+11.21%) As of 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
